JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 180 filers reported holding JUNO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.57 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $385,000 | +39.0% | 8,422 | +35.8% | 0.00% | +33.3% |
Q3 2017 | $277,000 | +52.2% | 6,202 | +2.2% | 0.00% | +50.0% |
Q2 2017 | $182,000 | +184.4% | 6,069 | +109.3% | 0.00% | +100.0% |
Q1 2017 | $64,000 | +100.0% | 2,900 | +70.6% | 0.00% | – |
Q4 2016 | $32,000 | -69.2% | 1,700 | -50.6% | 0.00% | -100.0% |
Q3 2016 | $104,000 | +2.0% | 3,444 | +29.9% | 0.00% | 0.0% |
Q2 2016 | $102,000 | +10.9% | 2,651 | +9.5% | 0.00% | 0.0% |
Q1 2016 | $92,000 | -15.6% | 2,420 | -2.0% | 0.00% | 0.0% |
Q4 2015 | $109,000 | +12.4% | 2,470 | +2.9% | 0.00% | 0.0% |
Q3 2015 | $97,000 | +24.4% | 2,400 | +65.5% | 0.00% | +100.0% |
Q2 2015 | $78,000 | -79.7% | 1,450 | -77.1% | 0.00% | -85.7% |
Q1 2015 | $385,000 | +73.4% | 6,337 | +49.1% | 0.01% | +40.0% |
Q4 2014 | $222,000 | – | 4,250 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
SIB LLC | 100,000 | $4,571,000 | 3.28% |
PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |